3-[4-(3-氨基丙氧基)-7-氯-3-(3,5-二甲基苯基)喹啉-6-基]苯酚 | 1021912-42-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 中文名称: 3-[4-(3-氨基丙氧基)-7-氯-3-(3,5-二甲基苯基)喹啉-6-基]苯酚
• 中文别名: 3-[4-(3-氨基丙氧基)-7-氯-3-(3,5-二甲基苯基)-6-喹啉基]苯酚
• 英文名称: 3-[4-(3-aminopropoxy)-7-chloro-3-(3,5-dimethylphenyl)quinolin-6-yl]phenol
• 英文别名: 3-[4-(3-Aminopropoxy)-7-chloro-3-(3,5-dimethylphenyl)-6-quinolinyl]phenol
• CAS: 1021912-42-4
• 化学式: C₂₆H₂₅ClN₂O₂
• 分子量: 432.95
• InChiKey: GXGVWEMSSIKHOZ-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  68.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氯-4-碘苯胺 在 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 、 溶剂黄146 、 三苯基膦 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二苯醚 、 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成 3-[4-(3-氨基丙氧基)-7-氯-3-(3,5-二甲基苯基)喹啉-6-基]苯酚
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2

  摘要：

  Agonists of somatostatin receptor subtype 2 (sst(2)) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst(2), and these were optimized to provide small molecules with sst(2) binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.

  DOI：

  10.1021/jm101501b

文献信息

• Somatostatin Agonists
  申请人：Eastman Brian

  公开号：US20090258853A1

  公开（公告）日：2009-10-15

  This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.

  本发明涉及一种能够激活生长抑素并且选择性地作用于生长抑素受体亚型SSTR2的化合物。这些化合物可用于治疗和预防糖尿病及其相关病理，包括视网膜病变、神经病变和肾病。其中许多化合物具有口服活性。因此，本发明的目的在于描述这些化合物，进一步地，描述生长抑素激动剂的特定优选立体异构体。另一个目的是描述制备这些化合物的方法和工艺。还有一个目的是描述使用这些化合物作为活性成分的方法和组合物。
• COMPOUND HAVING AGONISTIC ACTIVITY ON SOMATOSTATIN RECEPTOR, AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20150232478A1

  公开（公告）日：2015-08-20

  Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): [wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

  提供口服低毒性生长抑素受体亚型2激动剂。由于通式（I）所代表的化合物：[其中所有符号的含义与描述中所述的含义相同]，其盐，N-氧化物，溶剂化物或前药是非肽低分子化合物，具有强烈的生长抑素受体亚型2激动剂活性，因此该化合物可口服。此外，由于该化合物低毒性，因此该化合物可用于预防和/或治疗与生长抑素相关的疾病，例如肢端肥大症或胃肠梗阻。
• SOMATOSTATIN AGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1996196A2

  公开（公告）日：2008-12-03
• COMPOUND HAVING SOMATOSTATIN RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20160311794A1

  公开（公告）日：2016-10-27

  The present invention provides a somatostatin receptor subtype 2 agonist. A disclosed compound represented by the general formula (I): wherein all symbols have the same definitions as described in the specification; a salt thereof, an N-oxide thereof or a solvate thereof, or a prodrug of the foregoing is a low-molecular compound having strong somatostatin receptor subtype 2 agonistic activity, and thus can be administered in a simple manner, has high stability and has low toxicity. Therefore, the present compound is useful for prophylaxis and/or therapy of somatostatin-related diseases such as acromegaly and gastrointestinal obstruction.
• US9630976B2
  申请人：——

  公开号：US9630976B2

  公开（公告）日：2017-04-25